Repligen Co. (NASDAQ:RGEN) Stock Holdings Lifted by Pier Capital LLC

Pier Capital LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 30.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,053 shares of the biotechnology company’s stock after purchasing an additional 15,019 shares during the period. Repligen comprises about 1.2% of Pier Capital LLC’s holdings, making the stock its 29th largest position. Pier Capital LLC owned approximately 0.12% of Repligen worth $8,201,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Norges Bank bought a new position in Repligen during the fourth quarter valued at approximately $48,208,000. Bank of New York Mellon Corp lifted its stake in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC boosted its holdings in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Public Employees Retirement Association of Colorado increased its position in Repligen by 448.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock worth $20,293,000 after buying an additional 92,268 shares during the last quarter. Finally, Brown Capital Management LLC increased its position in Repligen by 5.8% during the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after buying an additional 83,416 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Up 1.5 %

Repligen stock opened at $146.70 on Wednesday. The firm has a market cap of $8.22 billion, a price-to-earnings ratio of 586.82, a P/E/G ratio of 4.35 and a beta of 0.94. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The firm has a fifty day moving average price of $143.63 and a two-hundred day moving average price of $158.28.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. The firm’s revenue was down 3.2% on a year-over-year basis. As a group, analysts forecast that Repligen Co. will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RGEN. Royal Bank of Canada reiterated an “outperform” rating and set a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. UBS Group dropped their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.